Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

230.57 +0.53 (+0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 985,061
Open 229.42
Bid (Size) 216.14 (1)
Ask (Size) 230.75 (5)
Prev. Close 230.04
Today's Range 226.43 - 230.83
52wk Range 189.44 - 304.79
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
Via Benzinga

Performance

YTD
-13.87%
-13.87%
1 Month
+19.99%
+19.99%
3 Month
+5.24%
+5.24%
6 Month
+1.13%
+1.13%
1 Year
-22.58%
-22.58%

More News

Read More
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
The Analyst Landscape: 27 Takes On Biogen
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Via Benzinga
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Via Investor's Business Daily
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
From Biogen Inc.
Via GlobeNewswire
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank
Via Benzinga
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
Via InvestorPlace
Topics Stocks
Exposures US Equities
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Via InvestorPlace
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
Via InvestorPlace
Biogen Reports Progress on Corporate Responsibility Priorities
From Biogen Inc.
Via GlobeNewswire
7 Retirement Stocks to Buy at a 52-Week Low in April
Via InvestorPlace
Topics Retirement
Exposures Pension
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Biogen Stock Leaped Nearly 5% Higher Today
Via The Motley Fool
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Via Benzinga
Exposures Product Safety
Biogen (BIIB) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Via Benzinga
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Via Benzinga
Topics Bonds
Exposures Debt Markets
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.